-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Iberdomide is a novel cerebellar E3 ligase modulator that has a stronger killing of tumor cells and immunostimulatory effects
This multi-cohort, open-label Phase 1/2 trial in Europe, Canada, and the United States enrolled multiple myeloma patients aged 18 years and older who
Between 5 December 2016 and 16 December 2020, the condition of 460 patients was evaluated, of whom 197 were enrolled in the group and received Iberdomide+ dexamethasone (90 in dose-increasing cohorts and 107 in dose-extended cohorts).
As of 2 June 2021, the dose-increasing cohort and the dose-extended cohort were followed up for a median of 5.
The most common adverse reactions of grade 3 and above were neutropenia (45%), anemia (28%), infection (27%), and thrombocytopenia (22%)
Overall, Iberdomide plus dexamethasone is generally safe in a large number of patients with multiple myeloma who have been pretreated and exhibit meaningful clinical activity that merits further evaluation
Original Source:
Sagar Lonial, et al.